Visugromab for cancer-related wasting and unintended weight loss

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2/3 interventional trial compares the investigational drug visugromab to a placebo in people with cancer-associated cachexia. Participants are assigned to receive visugromab or placebo by intravenous infusion once every four weeks and return for regular checkups and tests. Key outcomes include changes in body weight, appetite, physical activity and function, and monitoring of side effects and safety. The study is conducted at multiple international centers and follows participants over repeated monthly visits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Weight loss
* Advanced cancer

Exclusion Criteria:

* Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product

Where it's running

• Eastern Connecticut Hematology & Oncology
  Norwich, Connecticut, United States Recruiting
• Clermont Oncology Center
  Clermont, Florida, United States Recruiting
• Mid Florida Hematology and Oncology Centers
  Orange City, Florida, United States Recruiting
• Cleveland Clinic Martin Health
  Stuart, Florida, United States Recruiting
• Cleveland Clinic Weston Hospital
  Weston, Florida, United States Recruiting
• Augusta University Medical Center
  Augusta, Georgia, United States Recruiting

+29 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Trial Director
• Email: regulatory-006@catalym.com
• Phone: 49 8920006640

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Visugromab plus nivolumab, with or without docetaxel, for second-line treatment of metastatic non-squamous non-small cell lung cancer

  This trial tests whether adding the anti-GDF-15 antibody visugromab to nivolumab, with or without docetaxel, helps people with metastatic non-squamous NSCLC whose cancer progressed after first-line treatment that included a checkpoint inhibitor.

  Recruiting at 36 sites Phase 2 CatalYm GmbH · Birmingham, Alabama and 35 other locations · NCT07246863

• Visugromab plus Nivolumab and Lenvatinib versus Placebo plus Lenvatinib for unresectable or metastatic hepatocellular carcinoma after anti–PD-(L)1 therapy

  This trial will test whether adding visugromab and nivolumab to lenvatinib helps people with unresectable or metastatic liver cancer whose disease progressed after an anti–PD-(L)1 treatment.

  Recruiting at 29 sites Phase 2 CatalYm GmbH · Irvine, California and 28 other locations · NCT07219459

• Visugromab added to first-line immunochemotherapy for metastatic non-squamous NSCLC

  This trial tests whether adding visugromab to standard immunochemotherapy (pembrolizumab, pemetrexed, carboplatin) helps people with newly diagnosed metastatic non-squamous NSCLC who do not have targetable mutations.

  Recruiting at 51 sites Phase 2 CatalYm GmbH · Birmingham, Alabama and 50 other locations · NCT07098988

• First-in-human test of QLS2319 in healthy adults and cancer cachexia

  This study tests QLS2319 in healthy adults and people with cancer cachexia to see if it is safe, tolerated, and how it behaves in the body, with a look at early signs of benefit.

  Recruiting Phase 1/2 Qilu Pharmaceutical Co., Ltd. · Hefei, Anhui and 1 other locations · NCT07735104

• Omega-3 supplements plus progressive resistance training for cancer-related muscle loss

  This study tests whether fish oil and a structured resistance-training program can help improve muscle status in adults with various cancers who are receiving treatment.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT07643558

• First-in-human testing of FID-022 in solid tumor patients

  This project will test an AI tool to spot early cancer-related weight loss and see if diet and exercise support are acceptable for people with newly diagnosed pancreatic cancer.

  Recruiting H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07249775

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.